“ Vaccines have been considered a promising approach for GBM for many years .”
BUFFALO, NY- September 9, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 5, 2024, entitled, “ Next-generation vaccines are showing promise against glioblastoma .”
As noted in this paper, glioblastoma (GBM) is a rare but highly lethal malignancy that predominantly affects adults. Each year, approximately 13,000 new GBM cases are diagnosed in the United States, with around 12,000 related deaths. Historically, GBM was considered synonymous with Grade IV astrocytoma; however, recent classifications now distinguish IDH mutant Grade IV astrocytoma as a separate pathology. GBM accounts for about 15% of primary brain tumors and 50% of adult gliomas, making it one of the deadliest forms of brain cancer.
In their editorial, researchers Robert O. Dillman and Daniela A. Bota from the Chao Family Comprehensive Cancer Center , Departments of Neurology and Neurological Surgery , at the University of California, Irvine , in Orange, California, explore various clinical and randomized trials for GBM patients. These include trials of therapies for patients enrolled before and after concurrent radiation therapy and temozolomide (RT/TMZ), as well as patient attrition in trials involving dendritic cell (DC) vaccines and autologous tumor antigens.
“Numerous randomized trials have failed to demonstrate an improvement in survival from enrollment prior to starting concurrent radiation therapy and temozolomide chemotherapy RT/TMZ.”
The authors also highlight that vaccines have been a promising approach for treating GBM. These vaccines have generally been well tolerated, with the most common adverse events being local injection reactions and mild to moderate “flu-like” symptoms, which are usually brief and self-limiting. Additionally, medical treatment is often carried out during surgery when the tumor is resected and injected intradermally.
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28636
Correspondence to: Daniela A. Bota - dbota@hs.uci.edu
Video short: https://www.youtube.com/watch?v=8EIAIUlcDiE
Keywords: cancer, glioblastoma, vaccines
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget :
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline , PubMed Central , Scopus , EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget , visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify , and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries , please contact media@impactjournals.com .
Oncotarget Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
Oncotarget
Commentary/editorial
Not applicable
Next-generation vaccines are showing promise against glioblastoma
5-Aug-2024
ROD is employed by Aivita Biotherapeutics. DAB reports no conflicts.